Background {#Sec1}
==========

Gynaecomastia, a benign proliferation of glandular breast tissue in males \[[@CR1]\] is thought to result from an imbalance between oestrogens and androgens \[[@CR1]\]. There are reports of gynaecomastia in HIV infected men before antiretroviral therapy (ART) was available, \[[@CR2]\] but most reports are in men on ART. The estimated prevalence ranges from 1.8 to 2.9% \[[@CR3]--[@CR5]\].

Early case reports and case series implicated nucleoside reverse transcriptase inhibitors (NRTIs) and protease inhibitors \[[@CR5]--[@CR8]\]. However, case control studies found that gynaecomastia was associated with exposure to the non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz, and the NRTIs stavudine and didanosine \[[@CR3], [@CR4], [@CR9]\]. Most reports of ART-associated gynaecomastia come from resource-rich settings, and there are few data from Africa and other resource-limited settings.

We describe the clinical characteristics of HIV infected patients with ART-associated gynaecomastia reported to the National HIV & Tuberculosis (TB) Health Care Worker Hotline in South Africa, clinical investigation and management, clinical outcomes and time to improvement and/or resolution of gynaecomastia.

Methods {#Sec2}
=======

We included all suspected gynaecomastia cases reported to the National HIV & TB Health Care Worker Hotline between June 2013 and July 2014. The hotline is based at the Medicines Information Centre, University of Cape Town, and provides telephonic advice to health care workers on the management of patients with HIV and/or tuberculosis, including adverse drug reactions (ADRs). Details of the service have been described elsewhere \[[@CR10]\].

We used a standardized data collection form to collect data on patient characteristics, clinical characteristics of gynaecomastia, serum testosterone results and medication history. We recorded the date of initiation of the current ART regimen and when gynaecomastia was first noted by the patient. We calculated time to onset of gynaecomastia as the time interval from initiation of the current ART regimen to the date when gynaecomastia was first noted by the patient. In four cases where the date when gynaecomastia was first noted was missing, we used the date of the hotline query to calculate time to gynaecomastia onset. We obtained follow-up information telephonically from the health care worker at one month and then monthly or at the next patient visit for at least 6 months. We classified outcomes as resolved, improved (reduction in breast size and/or pain), unchanged, deteriorated or unknown. All descriptive analysis was performed using STATA version 13.

Results {#Sec3}
=======

Patient characteristics {#Sec4}
-----------------------

The hotline received queries from health care workers about suspected gynaecomastia in 51 males between June 2013 and July 2014. This constituted 11% of the 475 patient-specific ADR queries received by the hotline during this period. The mean age of patients with suspected gynaecomastia was 34 years (SD 12) (Table [1](#Tab1){ref-type="table"}). Adolescents comprised 14% of the case series. At the time of reporting gynaecomastia to the hotline, 30/31 (97%) patients with a viral load result recorded were virologically suppressed (Table [1](#Tab1){ref-type="table"}). Gynaecomastia onset was slow, occurring after a median of 15 months, (IQR 6--42) on ART. Gynaecomastia was bilateral in 57% of patients (Table [1](#Tab1){ref-type="table"}).Table 1Patient characteristics and description of suspected gynaecomastia casesPatient characteristicN (%) (n = 51)Age (years), mean ± SD34 ± 12Age category Adolescent (10--17 years)7 (14%) Adult (≥18 years)36 (71%) Unknown8 (16%)Baseline CD4 count before ART initiation (mm^3^), mean ± SD188 ± 95Current viral load Viral load (\<50)26 (51%) Viral load (51--399)4 (8%) Viral load \>4001 (2%) Viral load unknown20 (39%)Characteristics of gynaecomastia Site  Unilateral16 (31%)  Bilateral29 (57%)  Unknown6 (12%)  Breast pain present10 (20%)Gynaecomastia onset (months on ART), median \[IQR\]15 \[6--42\]

Antiretroviral regimens and concomitant drugs {#Sec5}
---------------------------------------------

All gynaecomastia cases reported to the hotline were on efavirenz-containing ART. The NRTI backbone at the time of gynaecomastia onset was tenofovir and lamivudine/emtricitabine in 40 (78%) of patients, stavudine and lamivudine in 5 (10%), abacavir and lamivudine in 4 (8%), zidovudine and lamivudine in 1 (2%) of patients and unknown NRTI backbone in 1 (2%) patient.

Sixteen patients (31%) were taking concomitant drugs previously described to cause gynaecomastia in addition to efavirenz: isoniazid in 11 patients, isoniazid and stavudine in one patient, amlodipine and stavudine in one patient and stavudine in three patients.

Clinical investigations and patient outcomes {#Sec6}
--------------------------------------------

We obtained follow-up data on 35 patients (69%) with a median follow-up period of 4 months, (IQR 1--6).

Serum testosterone testing was performed in 25/35 (71%) patients, of which 19 were within the normal range, two cases had low testosterone, two cases had elevated testosterone and in two cases the result was not recorded.

Twenty nine patients (83%) discontinued efavirenz: 27 patients were switched to nevirapine and two patients were switched to lopinavir/ritonavir. Gynaecomastia resolved completely in 7 of these 29 patients, improved in 13 and was unchanged in two, with unknown outcome in 7.

Six patients continued efavirenz. Gynaecomastia improved in one patient and was unchanged in one patient, with unknown outcome in four patients.

Median time to first improvement of gynaecomastia was 3 months (IQR 2--4, range1--8) (Fig. [1](#Fig1){ref-type="fig"}). Complete resolution occurred after a median of 6 months (IQR 4--6, range 4--9).Fig. 1Kaplan Meier curve of time to improvement in patients with follow-up (n = 35)

Discussion {#Sec7}
==========

We describe a case series of 51 patients with gynaecomastia on efavirenz-based ART in South Africa. Efavirenz is the recommended NNRTI in the standard first-line ART regimen for adults in South Africa \[[@CR11]\]. These cases were reported to the National HIV & TB Health Care Worker Hotline and comprised 11% of patient-specific ADR queries over a 13 month period. In the 35 patients with follow-up data, the majority switched from efavirenz to an alternative antiretroviral, and the gynaecomastia improved after efavirenz withdrawal in 69%.

This is to our knowledge the largest case series of ART-associated gynaecomastia cases reported from Sub-Saharan Africa. A small case series from Nigeria reported on six patients with efavirenz-associated gynaecomastia, all of which resolved after withdrawal of efavirenz \[[@CR12]\]. Two cases of efavirenz-associated gynaecomastia were reported from Malawi, both of which improved after switching efavirenz to nevirapine \[[@CR13]\].

Efavirenz is known to be associated with gynaecomastia \[[@CR3], [@CR4], [@CR9]\]. The proposed mechanism from in vitro data is that efavirenz mimics the effects of oestrogen on breast tissue \[[@CR14]\]. Two other hypothesized mechanisms have been suggested for ART-associated gynaecomastia: immune restoration may increase breast tissue oestrogen availability, and efavirenz has been shown to increase the area under the curve of ethinyl oestradiol by at least 37%, thereby elevating the oestrogen--androgen ratio \[[@CR15]\].

Three cohort studies from Spain and Italy have reported ART-associated gynaecomastia prevalence between 1.8 and 2.9% \[[@CR3]--[@CR5]\], whilst the incidence from another Spanish study of 1400 HIV infected men followed up over 20 months was 2.4 per 100 person years on ART \[[@CR6]\]. A study from Nigeria of 2920 HIV infected patients reported an incidence of gynaecomastia of 10.7 per 100 person years over 8 years \[[@CR16]\].

Interestingly 7 (14%) of our case series were adolescents. In three of these adolescent patients, gynaecomastia improved after withdrawal of efavirenz, suggesting that efavirenz was a probable contributing cause. However, the physiological changes of puberty may also have contributed to gynaecomastia in the adolescent cases we describe.

In contrast, previous case series do not report any cases of gynaecomastia in adolescents \[[@CR6], [@CR7], [@CR12], [@CR15], [@CR17]--[@CR19]\]. Cross-sectional data from the general population has shown that gynaecomastia occurs in 4% of adolescent boys aged 10--19 years \[[@CR20]\]. There is limited data on ART-associated gynaecomastia in African children and adolescents \[[@CR21], [@CR22]\].

The clinical presentation of the gynaecomastia in our case series was primarily bilateral after several months on ART, as previously reported in other studies \[[@CR6], [@CR7], [@CR9], [@CR12]\]. Previous studies have reported virological suppression in 77--100% of patients at the time of onset of gynaecomastia \[[@CR6], [@CR8], [@CR12], [@CR15], [@CR19]\]. In our case series 31 of the 51 patients had a current viral load result at the time of reporting gynaecomastia to the hotline, with viral load \<400 copies/mL in 30/31 (97%).

The majority of patients were switched from efavirenz, after which gynaecomastia improved/resolved in the majority. This finding is similar to other case series where efavirenz was discontinued \[[@CR12], [@CR13], [@CR15]\], but it is noteworthy that other studies have reported improvement in patients, despite continuation of efavirenz \[[@CR4], [@CR8], [@CR9]\]. Time to complete resolution was slow in our case series and was comparable to other studies that have reported a resolution time ranging from two to nine months \[[@CR4], [@CR6], [@CR8], [@CR12], [@CR15]\].

Where it was quantified, the free testosterone was normal in the majority of our gynaecomastia cases. In contrast, Biglia et al. reported an association between hypogonadism and gynaecomastia \[[@CR3]\]. Typically, the hotline recommends that a free testosterone be done to exclude hypogonadism before switching efavirenz to nevirapine. Free testosterone quantification is not routinely available in many resource-limited settings. The usefulness of testosterone testing in African patients with efavirenz-associated gynaecomastia needs to be explored further.

This case series has limitations. There was limited data on the method of diagnosis of the gynaecomastia cases. Follow-up information could not be obtained on all patients. Information on the exclusion of other causes of gynaecomastia was not always available. Reports were collected and follow-up was done telephonically; hence patient histories, clinical findings and outcomes could not be verified by clinical assessment or by review of patient records. The cases we describe are not a random and unbiased sample of gynaecomastia cases in our setting; they are cases in which a health care worker requested assistance from the hotline advice service.

Conclusions {#Sec8}
===========

In conclusion, efavirenz-associated gynaecomastia is frequently the subject of ADR queries to the HIV & TB Health Care Worker Hotline, suggesting that health care workers in South Africa need guidance on the management of this ADR. In most cases, gynaecomastia cases reported to the hotline occurred after prolonged efavirenz exposure. Efavirenz was withdrawn in the majority of patients, in accordance with advice given by the hotline, and gynaecomastia improved slowly in the majority.

Further studies are needed to determine the incidence and risk factors of ART-associated gynaecomastia in African adolescents and adult men, the role of hypogonadism in gynaecomastia in this setting, and the optimal clinical management of gynaecomastia. Studies answering these questions are essential in order to provide evidence-based guidance to health care workers on the optimal investigation and management of this important treatment-limiting ADR.
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